On this page
Quick Reference
Overview and Recommendations
Background
- •Recurrence patterns in cervical cancer are categorized by anatomic distribution—local (vaginal vault/parametria), regional (pelvic/para-aortic nodes), and distant (visceral organs)—with approximately 30% to 50% of locally advanced cases relapsing after definitive therapy.
- •The temporal peak for recurrence occurs within the first 36 months of follow-up, making intensive surveillance during this window critical for identifying patients eligible for curative salvage therapy.
- •Surgical technique serves as a primary driver of local control; the landmark LACC trial demonstrated that minimally invasive radical results in significantly higher recurrence rates compared to open surgery (86.0% vs 96.5% 4.5-year DFS), leading to a global shift back to open surgical approaches.
- •Nodal status and biological markers such as tumor-related leukocytosis (WBC > 9,000/μL) and persistent high-risk (HPV) (ctDNA) identify high-risk phenotypes prone to early systemic failure.
- •Distant metastasis most frequently involves the lungs, followed by the liver and bone, with liver involvement serving as a particularly poor prognostic indicator for overall survival.
Evaluation
- •Suspect recurrence in any patient with a history of cervical cancer presenting with new-onset pelvic pain, unexplained weight loss, vaginal bleeding, or persistent lower extremity edema.
- •Perform a thorough physical examination including a speculum exam, bimanual pelvic exam, and palpation of supraclavicular and inguinal lymph nodes to identify accessible sites for biopsy.
- •Order a PET/CT or chest/abdomen/pelvis CT with IV contrast as the initial imaging modality to differentiate between isolated local recurrence and widely disseminated metastatic disease.
- •Obtain a tissue biopsy of the suspected recurrence whenever feasible; histological confirmation is mandatory before initiating toxic systemic therapy or proceeding to ultra-radical surgery.
- •Assess PD-L1 expression using the Combined Positive Score (CPS) on the biopsy specimen; a CPS ≥ 1 is the requisite threshold for the addition of to first-line systemic therapy.
- •Evaluate the neutrophil-to-lymphocyte ratio (NLR) and serum lactate dehydrogenase (LDH) as these markers provide independent prognostic value regarding progression-free survival.
- •Screen for sarcopenia and nutritional deficits using CT-based muscle body composite measurements in patients being considered for pelvic exenteration, as these factors predict high postoperative morbidity.
- •Utilize MRI for local staging in patients with suspected central pelvic recurrence to assess for bladder or rectal involvement and to determine the feasibility of an R0 (margin-negative) resection.
Management
- •Initiate first-line systemic therapy for metastatic or non-resectable recurrent disease with a quadruplet regimen:
- •Administer at 200 mg IV every 3 weeks or 400 mg IV every 6 weeks for patients with PD-L1 CPS ≥ 1; this addition reduces the risk of death by approximately 37-40%.
- •Dose at 15 mg/kg IV every 3 weeks, but exercise caution in patients with prior pelvic radiation due to a 10-15% risk of gastrointestinal perforations or fistulas.
- •Perform pelvic exenteration (en bloc resection of pelvic organs) for isolated central recurrences in previously irradiated fields where R0 resection is achievable; this offers a median overall survival of 38.7 months.
- •Utilize (SBRT) for oligometastatic disease (limited number of lesions), typically delivering 39 Gy in 3 fractions to achieve durable local control.
- •Consider laterally extended endopelvic resection (LEER) for recurrences involving the lateral pelvic wall, though this requires highly specialized surgical expertise to ensure clear margins.
- •Apply high-dose-rate (HDR) interstitial for localized failures in patients who are not surgical candidates, using gel spacers to protect the bladder and rectum from radiation toxicity.
- •Monitor for treatment-related toxicities, particularly immune-related adverse events from and hypertension or proteinuria from .
- •Refer patients with brain or cutaneous metastases for palliative radiotherapy or specialized molecularly-targeted protocols, as these sites signify advanced systemic spread and poor prognosis.
- •Transition to maintenance therapy following first-line chemotherapy in the recurrent setting, which has been shown to improve 3-year overall survival from 37.8% to 52.5% (NNT = 7).
Board Review — High Yield
- •LACC Trial — Landmark study proving open radical hysterectomy is superior to minimally invasive surgery for cervical cancer survival.
- •CPS ≥ 1 — The mandatory PD-L1 threshold required to prescribe pembrolizumab in the first-line metastatic setting.
- •Pelvic Exenteration — The only curative option for central pelvic recurrence after prior definitive radiation.
- •36 Months — The critical window during which the vast majority of cervical cancer recurrences manifest.
- •Bevacizumab Toxicity — High risk of bowel perforation and fistulas when used in previously irradiated pelvic fields.
- •HPV ctDNA — An emerging ultra-sensitive biomarker for detecting molecular relapse before radiographic evidence.
- •SBRT Dose — 39 Gy in 3 fractions is a standard regimen for treating oligometastatic nodal recurrences.
Deep Dive — Evidence Details
Patterns of Recurrence
- ▸Recurrence occurs in 30-50% of LACC patients, primarily within the first 3 years post-treatment.
- ▸The lungs are the most common site of distant metastatic spread.
- ▸Open radical hysterectomy is preferred over minimally invasive surgery to minimize local recurrence risk (NNH = 10).
Patterns of recurrence in cervical cancer are categorized by their anatomic distribution—local, regional, or distant—which fundamentally dictates the transition from curative salvage to palliative systemic [1]A1c[57]D5. Approximately 30% to 50% of patients with locally advanced cervical cancer (LACC) experience relapse following definitive (CRT) [3]A1b[9]A1b. The temporal peak for these failures occurs within the first 3 years of follow-up, necessitating intensive surveillance during this window [46]B3b[61]B3b.
Anatomic Distribution and Risk Factors
Recurrence typically manifests in three distinct compartments. Local failure involves the vaginal vault, cervix, or parametria; regional failure involves pelvic or para-aortic ; and distant failure involves visceral organs or non-regional nodes [1]A1c[51]B2a. The lungs are the most frequent site of distant metastasis, followed by the liver and bone [51]B2a.
Nodal status remains the most potent predictor of recurrence. The logarithmic odds of positive lymph nodes (LODDS) provides superior prognostic accuracy compared to traditional N-staging [47]B3b. Furthermore, tumor-related leukocytosis (TRL), defined as a white blood cell count >9,000/μL, identifies a highly aggressive phenotype associated with a myeloid-derived suppressor cell-mediated premetastatic niche and poor radiation response [41]B3b[68]B3b.
Surgical and Biological Drivers
Surgical technique significantly influences local control. The landmark LACC trial demonstrated that minimally invasive radical results in higher recurrence rates compared to open surgery (86.0% vs 96.5% 4.5-year DFS; HR 3.74, 95% CI 1.63-8.58); NNH = 10 to cause one additional recurrence or death [18]A1b[29]A1b[34]D5[60]B3b. Biologically, the persistence of high-risk (HPV) (ctDNA) following CRT serves as an ultra-sensitive biomarker, often detecting molecular relapse months before radiographic evidence [3]A1b[48]B2b[69]B2b.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Surgical Approach | Open radical hysterectomy is the standard of care [NCCN, 18, 34]. | MIS may be considered in highly selected <2cm tumors [17]A1b[60]B3b. | Strong | MIS is largely abandoned for routine use. |
| Nodal Management | Abandon surgery for primary CRT if nodes are positive [53]D5. | Complete hysterectomy followed by adjuvant CRT [53]D5. | Moderate | No significant difference in OS; morbidity profiles differ. |
Pearl: Most cervical cancer recurrences occur within 36 months, with nodal status and post-treatment HPV ctDNA persistence serving as the strongest predictors of systemic failure [3]A1b[47]B3b[61]B3b.
| Factor | Threshold/Criteria | Clinical Impact |
|---|---|---|
| Nodal Status | High LODDS or Lymph Node Ratio | Primary driver of distant failure [47]B3b |
| Tumor Size | >4 cm | Increased risk of local and regional relapse [44]B3b |
| Leukocytosis | WBC >9,000/μL | Marker of TRL and metastatic potential [41]B3b[68]B3b |
| Surgical Route | Minimally Invasive (MIS) | 3.7-fold increased risk of recurrence [18]A1b |
| HPV ctDNA | Detectable post-CRT | High specificity for residual/recurrent disease [3]A1b[69]B2b |
Local-Regional Recurrence
- ▸R0 resection is the strongest predictor of survival in local-regional recurrence, achieved in approximately 68% of exenteration cases [79].
- ▸Sarcopenia and nutritional risk factors are independent predictors of poor outcomes following ultra-radical salvage surgery [74].
- ▸Gel spacer-assisted HDR brachytherapy is an emerging technique to protect the bladder and rectum during salvage reirradiation [75].
Pelvic exenteration offers a median overall survival of 38.7 months for patients with isolated central recurrence, representing the only curative pathway when prior radiation precludes further standard therapy [79]C4. Salvage surgery is indicated for the 20–30% of patients who present with persistent local disease six months after definitive chemoradiotherapy [78]B2a. Achieving an R0 resection is the primary determinant of success; in a series of 100 cases, R0 was confirmed in 68%, while lateral or perineal positive margins significantly worsened the prognosis [79]C4. (NNT not calculable from reported data).
Pelvic Exenteration and Radical Salvage Surgery
Ultra-radical surgery involves the en bloc resection of pelvic organs, including the bladder (anterior), rectum (posterior), or both (total) [79]C4[83]C4. While historically associated with high morbidity, advancements in minimally invasive techniques have refined the procedure. Robotic-assisted total pelvic exenteration (TPE) provides a stepwise approach—including sidewall mobilization, ureteral identification, and mesorectal dissection—that may reduce surgical trauma [83]C4. Single-port laparoscopic and combined laparoscopic-transperineal endoscopic approaches (TpTPE) are also feasible, particularly for deep pelvic recurrences at the vaginal stump [76]B3b[81]C4. Despite these advances, the postoperative morbidity rate remains high at 37%, with a mortality rate of approximately 3% [79]C4.
Patient Selection and Prognostic Factors
Successful salvage requires meticulous patient selection based on both anatomical and physiological factors. Sarcopenia, identified via pre-operative CT muscle body composite measurements, and high nutritional risk scores are independent predictors of poor survival and increased postoperative morbidity [74]B3b. For lateral pelvic wall recurrences, laterally extended endopelvic resection (LEER) may be considered [82]C4. Relapse patterns often follow the target volumes defined by NRG Oncology/RTOG guidelines, and precise mapping is essential to avoid marginal misses during salvage planning [73]A1b.
Reirradiation and
Reirradiation in previously treated fields is a "challenging area" with no firm consensus guidelines, though it is increasingly considered for localized failures [77]C4. High-dose-rate (HDR) interstitial brachytherapy is the most common modality for salvage [77]C4. The use of gel spacers injected between the recurrent tumor and adjacent organs at risk (OARs), such as the rectum and bladder, significantly reduces the actual radiation dose delivered to these structures, potentially mitigating late toxicities [75]C4. However, clinicians must remain vigilant for catastrophic complications; for instance, entero-vascular fistulas have been reported following radiotherapy in patients who previously underwent pelvic exenteration [80]C4.
Quality of Life and Psychological Impact
Pelvic exenteration is a life-altering procedure with significant psychological sequelae. Survivors frequently experience post-traumatic stress reactions and depression, as measured by the Impact of Event Scale-Revised [72]C4. Despite these challenges, many patients report significant post-traumatic growth and maintain a quality of life comparable to other gynecologic cancer populations, though it remains lower than that of the general population [72]C4.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| in LEER | Absolute contraindication due to R0 impossibility [82]C4 | Feasible via laparoscopic approach with meticulous dissection [82]C4 | Level 4 | Expands eligibility for lateral salvage |
| Reirradiation Guidelines | Standardized protocols for / [77]C4 | No firm guidelines; brachytherapy preferred [77]C4 | Level 4 | Treatment must be highly individualized |
Pearl: R0 resection is the cornerstone of salvage; achieving clear margins in pelvic exenteration yields a median overall survival of 38.7 months, though clinicians must screen for sarcopenia and nutritional deficits to mitigate a 37% morbidity rate [74]B3b[79]C4.
| Approach | Key Features | Clinical Context |
|---|---|---|
| Total Pelvic Exenteration (TPE) | Resection of bladder, rectum, and reproductive organs [79]C4[83]C4 | Central recurrence involving multiple compartments |
| LEER | Laterally extended endopelvic resection [82]C4 | Lateral pelvic wall involvement |
| Robotic/Laparoscopic PE | Minimally invasive, improved visualization [76]B3b[83]C4 | Selected patients to reduce surgical trauma |
| TpTPE | Combined laparoscopic and transperineal approach [81]C4 | Deep pelvic recurrence involving the vaginal stump |
| Anterior/Posterior PE | Compartmentalized resection sparing the rectum or bladder [79]C4 | Isolated anterior or posterior compartment failure |
Distant Metastatic Disease
- ▸First-line therapy for metastatic disease (CPS ≥1) utilizes a quadruplet regimen of platinum, paclitaxel, bevacizumab, and pembrolizumab [86].
- ▸Bispecific antibodies targeting PD-1 and CTLA-4 (e.g., cadonilimab, QL1706) show promising median OS of 18.6 months and efficacy after prior PD-1 failure [93, 99].
- ▸Liver metastasis and elevated inflammatory markers (NLR, LDH) are strong negative prognostic indicators for survival in the metastatic setting [90, 96, 99].
Systemic therapy for distant metastatic cervical cancer (Stage IVB or recurrence) prioritizes triplet or quadruplet regimens to maximize overall survival (OS) in patients with preserved performance status. While palliative chemotherapy was historically the standard, the integration of and anti-angiogenic agents has shifted the therapeutic goal toward durable disease control. For patients with FIGO stage IVB disease restricted to para-aortic lymph metastasis below the renal vessels, curative-intent MRI-guided adaptive (IGABT) remains a feasible option within a multimodal framework [27]B2b.
First-Line Systemic Regimens
The current standard for first-line treatment of persistent, recurrent, or metastatic cervical cancer is the combination of platinum-based chemotherapy ( or ) and , often supplemented with (15 mg/kg). NCCN guidelines recommend the addition of (200 mg every 3 weeks or 400 mg every 6 weeks) for patients whose tumors express PD-L1 with a Combined Positive Score (CPS) ≥1 [86]C4. This quadruplet approach targets both the vascular endothelial growth factor (VEGF) pathway and the programmed cell death receptor-1 (PD-1) pathway to overcome immune evasion [86]C4.
Emerging evidence suggests that bispecific antibodies (BsAbs) targeting both PD-1 and CTLA-4, such as cadonilimab or QL1706, may offer superior efficacy compared to PD-1 inhibitors alone [85]B3b[99]B2b. In a phase 1/1b study, QL1706 demonstrated a median OS of 18.6 months and a median progression-free survival (PFS) of 4.2 months in patients with advanced cervical cancer [99]B2b. Furthermore, cadonilimab has shown clinical activity even in patients who have failed prior PD-1/PD-L1 inhibitor therapy, suggesting that dual checkpoint blockade can overcome secondary resistance [93]C4.
Metastatic Patterns and Rare Sites
Cervical cancer typically disseminates to the lungs, bones, liver, and distant lymph nodes [87]C4. Liver metastasis is a particularly poor prognostic indicator, correlating with significantly shorter OS [99]B2b. Rare sites of involvement include the brain and skin, both of which signify advanced systemic spread and poor outcomes [88]C4.
- Brain Metastasis: Extremely rare with no established standard of care. Palliative resection or is often employed, though response is typically poor [88]C4.
- Cutaneous Metastasis: Occurs in approximately 1% of patients and may present as nodules that mimic or rashes [87]C4. Immediate biopsy is required for diagnosis. Complete metabolic response has been documented following aggressive molecularly-targeted therapy including paclitaxel, carboplatin, bevacizumab, and zoledronic acid [87]C4.
Biomarkers and Prognostic Nomograms
Predicting response to relies on clinical and laboratory markers beyond PD-L1 status. A high neutrophil-to-lymphocyte ratio (NLR), particularly when elevated both pre- and post-treatment, is associated with worse PFS (HR 2.14, 95% CI 1.42-3.22; NNT not calculable from reported data) [90]B3b. Similarly, elevated serum lactate dehydrogenase (LDH) and the systemic immune inflammation index (SII) serve as independent predictors of poor treatment outcomes [96]B3b[99]B2b. Validated nomograms incorporating these variables, along with performance status and metastatic site, allow for individualized risk stratification and clinical decision-making [95]B3b.
Controversies and Guideline Disagreement
| Question | Position A (NCCN/ASCO) | Position B (Emerging Data) | Strength | Implication |
|---|---|---|---|---|
| First-line ICI Choice | Pembrolizumab + Chemo + Bev for CPS ≥1 [86]C4. | Bispecific PD-1/CTLA-4 (e.g., Cadonilimab) + Chemo [85]B3b[93]C4. | Moderate | Bispecifics may provide deeper responses in PD-L1 low tumors. |
| Post-PD-1 Failure | Transition to non-ICI systemic therapy or clinical trial. | Rechallenge with dual PD-1/CTLA-4 blockade [93]C4. | Low | Potential for salvage in immunotherapy-refractory disease. |
Pearl: The addition of pembrolizumab to platinum-based chemotherapy and bevacizumab is the standard of care for PD-L1+ (CPS ≥1) metastatic disease, though dual PD-1/CTLA-4 bispecific antibodies are emerging as potent alternatives for both first-line and refractory settings [86]C4[93]C4[99]B2b.
| Regimen | Median PFS (Months) | Median OS (Months) | Key Biomarker | Source |
|---|---|---|---|---|
| QL1706 (PD-1/CTLA-4) | 4.2 | 18.6 | Liver Met (Poor OS) | [99]B2b |
| Cadonilimab (PD-1/CTLA-4) | NR | NR | Prior PD-1 Failure | [93]C4 |
| Pembrolizumab + Chemo + Bev | NR | NR | CPS ≥1 | [86]C4 |
| Ipilimumab (Post-CRT) | NR | NR | T-cell activation | [71]B2b |
Oligometastatic Disease
- ▸SBRT at doses of 39 Gy in 3 fractions provides effective local control for oligometastatic lymph node recurrences.
- ▸SBRT boost (21 Gy in 3 fractions) is a validated alternative for patients ineligible for standard brachytherapy.
- ▸Maintenance therapy after first-line treatment for metastatic disease improves 3-year OS from 37.8% to 52.5%.
Metastasis-directed therapy (MDT) using ( ) provides high rates of local control for patients with limited disease burden. In a cohort of 85 patients with 100 recurrent or oligometastatic lesions—primarily involving —SBRT delivered at a median dose of 39 Gy in 3 fractions (BED 90 Gy) achieved durable responses [104]B3b. This approach is particularly effective for salvage in patients with previous radiation exposure, as SBRT allows for highly conformal dose delivery to isolated sites [104]B3b[108]B2a[110]D5.
SBRT as a Boost Alternative
SBRT boost serves as a critical alternative for patients with locally advanced or recurrent disease who are ineligible for (BCT) due to anatomical constraints, resource limitations, or comorbidities [102]B2b[107]A1a[111]D5. Prospective phase I/II trials established a recommended SBRT boost dose of 21 Gy in 3 fractions following 45 Gy of whole-pelvic radiotherapy [102]B2b[105]B2b. While 1-year local control rates for SBRT boost range from 86% to 100%, dosimetric studies indicate that SBRT is generally inferior to image-guided BCT in target coverage and sparing of adjacent organs at risk [103]C4[109]D5[111]D5.
Maintenance Therapy and Systemic Control
Maintenance therapy (MT) following first-line chemotherapy significantly improves long-term outcomes in the recurrent or metastatic setting. Patients receiving MT achieved a 3-year (OS) rate of 52.5% compared to 37.8% in those without maintenance (HR 0.61, 95% CI 0.41-0.89) [106]B3b. This absolute risk reduction of 14.7% translates to an NNT = 7 to prevent one death at 3 years [106]B3b.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| SBRT vs. BCT | BCT is the mandatory gold standard for dose escalation [109]D5[110]D5. | SBRT is a safe, effective alternative when BCT is unfeasible [107]A1a[111]D5. | Moderate | SBRT should not be used electively if BCT is possible. |
Pearl: MDT with SBRT offers high local control for oligometastatic lesions, but it should only replace brachytherapy when the latter is technically unfeasible [104]B3b[109]D5[110]D5.
| Parameter | Clinical Finding | Evidence |
|---|---|---|
| Median SBRT Dose | 39 Gy in 3 fractions (BED 90 Gy) | [104]B3b |
| 1-Year Local Control | 86% – 100% (as BCT alternative) | [111]D5 |
| Recommended Boost | 21 Gy in 3 fractions | [102]B2b[105]B2b |
| Common Sites | Lymph nodes (89%), Distant (8%), Local (3%) | [104]B3b |
Prognosis of Recurrent Disease
- ▸The addition of pembrolizumab to first-line chemotherapy reduces the risk of death by approximately 40% (HR 0.60–0.63) [2, 115].
- ▸Ultrasensitive ctDNA and cHPV DNA detection can predict clinical relapse with a hazard ratio for progression of 4.1 [3, 69].
- ▸Open radical hysterectomy is associated with superior disease-free survival compared to minimally invasive approaches (aHR for recurrence 1.88) [18, 123].
Survival outcomes in recurrent cervical cancer have historically been poor, with median overall survival (OS) often falling below 12 months in the pre-immunotherapy era [14]A1b[54]D5. The integration of immune checkpoint inhibitors (ICIs) has shifted the prognostic curve. Adding to chemotherapy (± ) reduces the risk of death by approximately 37–40% (HR 0.60–0.63; NNT not calculable from reported data) [2]A1b[115]A1a. While chemoradiotherapy (CRT) provides a 6% absolute improvement in 5-year survival for locally advanced disease (HR 0.81, 95% CI 0.71-0.91), the NNT = 17 to prevent one death at 5 years [4]A1a.
Prognostic Determinants
Clinical performance status remains the most robust predictor of survival. Patients with an status of 0 have significantly better outcomes than those with a status of 1 or 2 [2]A1b[10]A1b. The site of recurrence also dictates the potential for salvage. Locoregional failures in a non-irradiated field may be amenable to curative-intent surgery or radiation. Conversely, distant metastatic disease carries a mortality rate exceeding 90% at 5 years [1]A1c[124]B2c. Validated GOG nomograms incorporate histology, race, and tumor size to predict 2-year PFS and 5-year OS [124]B2c.
Molecular and Long-Term Outcomes
Ultrasensitive circulating tumor DNA (ctDNA) and circulating HPV DNA (cHPV) now allow for the detection of molecular relapse months before clinical evidence [3]A1b[69]B2b. Persistent ctDNA after treatment strongly correlates with poor PFS (HR 4.1) [3]A1b. Survivorship is often marred by chronic fatigue, pelvic pain, and psychological distress [29]A1b[30]A1b. Bevacizumab use carries a 10–15% risk of perforations or fistulas in previously irradiated fields, which significantly impacts long-term morbidity [30]A1b.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Surgical Approach | Open radical is the standard to minimize recurrence [18]A1b[34]D5[60]B3b. | Minimally invasive surgery (MIS) shows higher mortality [18]A1b[123]B3b. | High (Level 1b) | NCCN/ASCO now recommend open surgery [34]D5[123]B3b. |
| Treatment De-escalation | Immunotherapy alone may be feasible in highly selected patients [119]C4. | Chemo-immunotherapy remains the preferred first-line standard [2]A1b[119]C4. | Low (Level 4) | De-escalation is currently experimental [119]C4. |
Pearl: The prognosis of recurrent cervical cancer is increasingly defined by molecular markers and PD-L1 status, with triplet/quadruplet immunotherapy-based regimens reducing the risk of death by nearly 40% compared to chemotherapy alone [2]A1b[115]A1a.
| Factor | Good Prognosis | Poor Prognosis |
|---|---|---|
| Performance Status | ECOG 0 | ECOG ≥1 [2]A1b[10]A1b |
| Recurrence Site | Pelvic (non-irradiated) | Distant or Para-aortic [1]A1c[126]B3b |
| Prior Treatment | Treatment-naive | Prior cisplatin or radiation [5]A1b[54]D5 |
| Biomarkers | Undetectable ctDNA | Persistent ctDNA or cHPV [3]A1b[69]B2b |
| Hematology | Normal WBC count | Tumor-related leukocytosis [41]B3b |
Related Pages
Part of the Cervical Cancer family. Cross-cutting management is split across dedicated child pages:
- — diagnostic page (definition, epidemiology, staging, biomarkers, prognosis)
- — operations by stage, fertility-sparing options, sentinel node mapping, adjuvant triggers (Sedlis / Peters)
- — EBRT + image-guided brachytherapy + concurrent chemoradiation, dose / fractionation, OAR constraints
- — concurrent / adjuvant / metastatic chemotherapy, targeted therapy, immune checkpoint inhibitors
- — early integration, symptom management, palliative procedures, end-of-life care
- — post-treatment surveillance schedule, late toxicity, survivorship, patient counselling
Pearl: Use these links to hop between management modalities; the parent Cervical Cancer page carries diagnosis + staging that informs every decision here.
References
- [1]
Abu-Rustum NR, Campos SM, Amarnath S et al.. “Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2026). PMID: 41825134 ↗
L1GUIDELINECited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [2]
Lorusso D, Colombo N, Dubot C et al.. “Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 39393777 ↗
L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [3]
Mayadev J, Vázquez Limón JC, Ramírez Godinez FJ et al.. “Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40500687 ↗
L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [4]
. “Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 19001332 ↗
L1SR_OBSCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [5]
Kitagawa R, Katsumata N, Shibata T et al.. “Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25732161 ↗
L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [6]
Xia L, Zhang K, Tang Y et al.. “Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40561369 ↗
L1RCTCited in: Patterns of Recurrence - [7]
Lorusso D, Ferrandina G, Pignata S et al.. “Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 19605508 ↗
L4TRIAL_NONRANDOMCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [8]
Thaker PH, Salani R, Brady WE et al.. “A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 27998970 ↗
L4TRIAL_NONRANDOMCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [9]
Monk BJ, Toita T, Wu X et al.. “Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.” The Lancet. Oncology (2023). PMID: 38039991 ↗
L1RCTCited in: Patterns of Recurrence - [10]
Mileshkin LR, Moore KN, Barnes EH et al.. “Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial.” The Lancet. Oncology (2023). PMID: 37080223 ↗
L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [11]
Oaknin A, Moore K, Meyer T et al.. “Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.” The Lancet. Oncology (2024). PMID: 38608691 ↗
L4RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [12]
Schuurman TN, Schaafsma M, To KH et al.. “Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study.” The Lancet. Oncology (2023). PMID: 37952541 ↗
L3COHORTCited in: Patterns of Recurrence - [13]
Höckel M, Wolf B, Schmidt K et al.. “Surgical resection based on ontogenetic cancer field theory for cervical cancer: mature results from a single-centre, prospective, observational, cohort study.” The Lancet. Oncology (2019). PMID: 31383547 ↗
L2COHORTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [14]
Symonds RP, Gourley C, Davidson S et al.. “Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial.” The Lancet. Oncology (2015). PMID: 26474517 ↗
L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [15]
Vergote I, González-Martín A, Fujiwara K et al.. “Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.” The New England journal of medicine (2024). PMID: 38959480 ↗
L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [16]
Tewari KS, Monk BJ, Vergote I et al.. “Survival with Cemiplimab in Recurrent Cervical Cancer.” The New England journal of medicine (2022). PMID: 35139273 ↗
L1RCTCited in: Patterns of Recurrence - [17]
Plante M, Kwon JS, Ferguson S et al.. “Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer.” The New England journal of medicine (2024). PMID: 38416430 ↗
L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [18]
Ramirez PT, Frumovitz M, Pareja R et al.. “Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.” The New England journal of medicine (2018). PMID: 30380365 ↗
L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [19]
Tewari KS, Sill MW, Long HJ et al.. “Improved survival with bevacizumab in advanced cervical cancer.” The New England journal of medicine (2014). PMID: 24552320 ↗
L1RCTCited in: Patterns of Recurrence - [20]
Vergote I, Van Nieuwenhuysen E, O'Cearbhaill RE et al.. “Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37651655 ↗
L4TRIAL_NONRANDOMCited in: Patterns of Recurrence - [21]
Xu Q, Wang J, Sun Y et al.. “Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35192397 ↗
L4TRIAL_NONRANDOMCited in: Patterns of Recurrence - [22]
O'Malley DM, Neffa M, Monk BJ et al.. “Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 34932394 ↗
L4TRIAL_NONRANDOMCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [23]
Naumann RW, Hollebecque A, Meyer T et al.. “Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31487218 ↗
L4TRIAL_NONRANDOMCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [24]
Lécuru F, Mathevet P, Querleu D et al.. “Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21444878 ↗
L2TRIAL_NONRANDOMCited in: Patterns of Recurrence - [25]
Birrer M, Li G, Yunokawa M et al.. “Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial.” JAMA oncology (2024). PMID: 39052242 ↗
L4RCTCited in: Patterns of Recurrence - [26]
Cho WK, Park W, Kim SW et al.. “Postoperative Hypofractionated Intensity-Modulated Radiotherapy With Concurrent Chemotherapy in Cervical Cancer: The POHIM-CCRT Nonrandomized Controlled Trial.” JAMA oncology (2024). PMID: 38662364 ↗
L2RCTCited in: Patterns of Recurrence - [27]
Pötter R, Tanderup K, Schmid MP et al.. “MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study.” The Lancet. Oncology (2021). PMID: 33794207 ↗
L2TRIAL_NONRANDOMCited in: Patterns of Recurrence, Distant Metastatic Disease - [28]
Coleman RL, Lorusso D, Gennigens C et al.. “Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.” The Lancet. Oncology (2021). PMID: 33845034 ↗
L4TRIAL_NONRANDOMCited in: Patterns of Recurrence - [29]
Frumovitz M, Obermair A, Coleman RL et al.. “Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial.” The Lancet. Oncology (2020). PMID: 32502445 ↗
L1TRIAL_NONRANDOMCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [30]
Penson RT, Huang HQ, Wenzel LB et al.. “Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).” The Lancet. Oncology (2015). PMID: 25638326 ↗
L1TRIAL_NONRANDOMCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [31]
Mayadev JS, Enserro D, Lin YG et al.. “Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer.” JAMA oncology (2020). PMID: 31774464 ↗
L4TRIAL_NONRANDOMCited in: Patterns of Recurrence - [32]
Moore DH. “Chemotherapy for advanced, recurrent, and metastatic cervical cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2008). PMID: 18267059 ↗
L5REVIEW_NARRATIVECited in: Patterns of Recurrence - [33]
Dyer BA, Zamarin D, Eskandar RN et al.. “Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30659133 ↗
L5REVIEW_NARRATIVECited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [34]
Pennington KP, Urban RR, Gray HJ. “Revisiting Minimally Invasive Surgery in the Management of Early-Stage Cervical Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30659132 ↗
L5REVIEW_NARRATIVECited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [35]
Hong DS, Concin N, Vergote I et al.. “Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 31796521 ↗
L4TRIAL_NONRANDOMCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [36]
Oaknin A, Ghamande SA, Kasamatsu Y et al.. “Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38165683 ↗
L4TRIAL_NONRANDOMCited in: Patterns of Recurrence - [37]
Kidd EA, Grigsby PW. “Intratumoral metabolic heterogeneity of cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18698042 ↗
L2TRIAL_NONRANDOMCited in: Patterns of Recurrence - [38]
Tewari KS. “Immune Checkpoint Blockade in PD-L1-Positive Platinum-Refractory Cervical Carcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31026210 ↗
L5CASE_REPORTCited in: Patterns of Recurrence - [39]
Wang X, Zhang Y, Wang C et al.. “Efficacy and safety of first-line therapies for persistent, recurrent, or metastatic cervical cancer: a systematic review and exploratory network meta-analysis of immunotherapy.” Frontiers in immunology (2026). PMID: 42079658 ↗
L1SR_OBSCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [40]
Park JY, Kim DY, Kim JH et al.. “Management of occult invasive cervical cancer found after simple hysterectomy.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 19858083 ↗
L3OTHERCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [41]
Cho Y, Kim KH, Yoon HI et al.. “Tumor-related leukocytosis is associated with poor radiation response and clinical outcome in uterine cervical cancer patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 27502717 ↗
L3OTHERCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [42]
Li Z, Yu CP, Zhong Y et al.. “Sam68 expression and cytoplasmic localization is correlated with lymph node metastasis as well as prognosis in patients with early-stage cervical cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 21700735 ↗
L3OTHERCited in: Patterns of Recurrence - [43]
Nakamura K, Abarzua F, Hongo A et al.. “Hepatocyte growth factor activator inhibitor-2 (HAI-2) is a favorable prognosis marker and inhibits cell growth through the apoptotic pathway in cervical cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 18689863 ↗
L3OTHERCited in: Patterns of Recurrence - [44]
Kodama J, Hasengaowa, Kusumoto T et al.. “Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17032700 ↗
L3OTHERCited in: Patterns of Recurrence - [45]
Ma J, Wang G, Wang W et al.. “Extended-field intensity-modulated radiation therapy and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic or common iliac lymph nodes: a multicenter prospective cohort study.” Journal of gynecologic oncology (2026). PMID: 42210768 ↗
L2COHORTCited in: Patterns of Recurrence - [46]
Wei Y, Song F, Wang W. “Expression levels of serum SCC, HE4, and TSGF in cervical cancer patients and their correlation with recurrence: a retrospective study.” Frontiers in medicine (2026). PMID: 42200085 ↗
L3COHORTCited in: Patterns of Recurrence - [47]
Zhang L, Yang J, Zhang P et al.. “Association between log odds of positive lymph nodes and survival in surgically treated cervical cancer patients: a SEER database-based cohort study.” World journal of surgical oncology (2026). PMID: 41998619 ↗
L3COHORTCited in: Patterns of Recurrence - [48]
Han K, Zou J, Zhao Z et al.. “Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 37972346 ↗
L2OTHERCited in: Patterns of Recurrence - [49]
Ogasawara A, Suzuki S, Oda K et al.. “Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025).” Gynecologic oncology (2026). PMID: 42013608 ↗
L4TRIAL_NONRANDOMCited in: Patterns of Recurrence - [50]
Van Nieuwenhuysen E, Vergote I, Randall LM et al.. “Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.” Gynecologic oncology (2026). PMID: 42000372 ↗
L4TRIAL_NONRANDOMCited in: Patterns of Recurrence - [51]
Yang Y, Yu M, Zeng M. “Distant metastasis in patients with cervical cancer: A systematic review and meta-analysis of incidence rates and common sites.” International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2026). PMID: 42171512 ↗
L2SR_OBSCited in: Patterns of Recurrence - [52]
Saini SK, Srivastava S, Goel A et al.. “Outcomes of Stage IVA Cervical Cancer Treated with Radiation Therapy: A Systematic Review and Meta-Analysis.” International journal of radiation oncology, biology, physics (2026). PMID: 42034194 ↗
L2SR_OBSCited in: Patterns of Recurrence - [53]
Wenzel HHB, Olthof EP, Bekkers RLM et al.. “Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis - A review.” Cancer treatment reviews (2022). PMID: 34773774 ↗
L5REVIEW_NARRATIVECited in: Patterns of Recurrence, Distant Metastatic Disease - [54]
Pectasides D, Kamposioras K, Papaxoinis G et al.. “Chemotherapy for recurrent cervical cancer.” Cancer treatment reviews (2008). PMID: 18657909 ↗
L5REVIEW_NARRATIVECited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [55]
Monk BJ, Enomoto T, Kast WM et al.. “Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials.” Cancer treatment reviews (2022). PMID: 35413489 ↗
L5REVIEW_NARRATIVECited in: Patterns of Recurrence - [56]
Tolcher A, Hamilton E, Coleman RL. “The evolving landscape of antibody-drug conjugates in gynecologic cancers.” Cancer treatment reviews (2023). PMID: 37023499 ↗
L5REVIEW_NARRATIVECited in: Patterns of Recurrence - [57]
Gennigens C, Jerusalem G, Lapaille L et al.. “Recurrent or primary metastatic cervical cancer: current and future treatments.” ESMO open (2022). PMID: 36108558 ↗
L5REVIEW_NARRATIVECited in: Patterns of Recurrence - [58]
Cabel L, Bonneau C, Bernard-Tessier A et al.. “HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer.” ESMO open (2021). PMID: 34022731 ↗
L2OTHERCited in: Patterns of Recurrence - [59]
Tu H, Huang H, Li Y et al.. “Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer.” The New England journal of medicine (2025). PMID: 41092328 ↗
L1OTHERCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [60]
Melamed A, Margul DJ, Chen L et al.. “Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer.” The New England journal of medicine (2018). PMID: 30379613 ↗
L3OTHERCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [61]
Brunson A, Wun T, Abrahão R et al.. “Metastatic Recurrence Among Adolescents and Young Adults With Cancer.” JAMA oncology (2026). PMID: 41296369 ↗
L3OTHERCited in: Patterns of Recurrence - [62]
Lheureux S, Butler MO, Clarke B et al.. “Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.” JAMA oncology (2018). PMID: 29145543 ↗
L2OTHERCited in: Patterns of Recurrence - [63]
Jiang Q, Zhang Z, Zhou J et al.. “The role of p53-mediated signaling pathways in nicotine-induced cancer: a systematic review.” Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2026). PMID: 42250592 ↗
L5SR_OBSCited in: Patterns of Recurrence - [64]
Liu Y, Hu Y, Wang H et al.. “Clinicopathological and Prognostic Characteristics of Gastric-Type Endocervical Adenocarcinoma: A Nested Case-Control Study.” Cancers (2026). PMID: 41976390 ↗
L3CASE_CONTROLCited in: Patterns of Recurrence - [65]
Miller KM, Friedman CF. “Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 35947045 ↗
L5OTHERCited in: Patterns of Recurrence - [66]
Tewari KS, Monk BJ. “New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 25104084 ↗
L5REVIEW_NARRATIVECited in: Patterns of Recurrence - [67]
Seo A, Xiao W, Gjyshi O et al.. “Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Patients with Cervical Cancer Undergoing Definitive Chemoradiation.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39680029 ↗
L2OTHERCited in: Patterns of Recurrence - [68]
Sasano T, Mabuchi S, Kozasa K et al.. “The Highly Metastatic Nature of Uterine Cervical/Endometrial Cancer Displaying Tumor-Related Leukocytosis: Clinical and Preclinical Investigations.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29752277 ↗
L3OTHERCited in: Patterns of Recurrence - [69]
Sivars L, Jylhä C, Crona Guterstam Y et al.. “Cell-Free Human Papillomavirus DNA Is a Sensitive Biomarker for Prognosis and for Early Detection of Relapse in Locally Advanced Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38669077 ↗
L2OTHERCited in: Patterns of Recurrence, Prognosis of Recurrent Disease - [70]
Lee MY, Chou CY, Tang MJ et al.. “Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18676743 ↗
L4OTHERCited in: Patterns of Recurrence - [71]
Da Silva DM, Enserro DM, Mayadev JS et al.. “Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929).” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32816895 ↗
L2OTHERCited in: Patterns of Recurrence, Distant Metastatic Disease, Prognosis of Recurrent Disease - [72]
Thompson LMA, Loecher N, Albizu-Jacob A et al.. “Post-traumatic reactions and quality of life after pelvic exenteration for gynecologic cancer: a retrospective cohort study.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2024). PMID: 39404886 ↗
L4COHORTCited in: Local-Regional Recurrence - [73]
Mittal P, Chopra S, Charnalia M et al.. “Patterns of Relapse After Adjuvant Chemoradiation for Cervical Cancer in a Phase 3 Clinical Trial (PARCER): An Evaluation of Updated NRG Oncology/RTOG Target Delineation Guidelines.” International journal of radiation oncology, biology, physics (2022). PMID: 35157993 ↗
L1RCTCited in: Local-Regional Recurrence - [74]
Seebacher V, Rockall A, Nobbenhuis M et al.. “The impact of nutritional risk factors and sarcopenia on survival in patients treated with pelvic exenteration for recurrent gynaecological malignancy: a retrospective cohort study.” Archives of gynecology and obstetrics (2022). PMID: 34734326 ↗
L3COHORTCited in: Local-Regional Recurrence - [75]
Okuma K, Murakami N, Inaba K et al.. “Gel spacer-assisted salvage brachytherapy for pelvic recurrence after definitive chemoradiotherapy in cervical cancer: A single-institution retrospective study.” Brachytherapy (2025). PMID: 40769797 ↗
L4COHORTCited in: Local-Regional Recurrence - [76]
Yu JH, Tong CJ, Huang QD et al.. “Long-term outcomes of pelvic exenterations for gynecological malignancies: a single-center retrospective cohort study.” BMC cancer (2024). PMID: 38229045 ↗
L3COHORTCited in: Local-Regional Recurrence - [77]
Sadozye AH. “Re-irradiation in Gynaecological Malignancies: A Review.” Clinical oncology (Royal College of Radiologists (Great Britain)) (2018). PMID: 29233573 ↗
L4SR_OBSCited in: Local-Regional Recurrence - [78]
Conte C, Della Corte L, Pelligra S et al.. “Assessment of Salvage Surgery in Persistent Cervical Cancer after Definitive Radiochemotherapy: A Systematic Review.” Medicina (Kaunas, Lithuania) (2023). PMID: 36837394 ↗
L2SR_OBSCited in: Local-Regional Recurrence - [79]
Bacalbasa N, Balescu I, Vilcu M et al.. “Pelvic Exenteration for Locally Advanced and Relapsed Pelvic Malignancies - An Analysis of 100 Cases.” In vivo (Athens, Greece) (2019). PMID: 31662557 ↗
L4SR_OBSCited in: Local-Regional Recurrence - [80]
Hwang IS, Hur SY. “Entero-vascular fistula following radiotherapy in a patient with recurrent cervical cancer post-pelvic exenteration: a case report.” BMC women's health (2025). PMID: 40634912 ↗
L4CASE_REPORTCited in: Local-Regional Recurrence - [81]
Ohno R, Matsumoto Y, Nagano H et al.. “Combined laparoscopic and transperineal endoscopic total pelvic exenteration for the vaginal stump recurrence of cervical cancer.” Journal of gynecologic oncology (2022). PMID: 34910397 ↗
L4CASE_REPORTCited in: Local-Regional Recurrence - [82]
Kanao H, Aoki Y, Fusegi A et al.. “Should indications for laterally extended endopelvic resection (LEER) exclude patients with sciatica?” Journal of gynecologic oncology (2020). PMID: 32808494 ↗
L4CASE_REPORTCited in: Local-Regional Recurrence - [83]
Konstantinidis IT, Chu W, Tozzi F et al.. “Robotic Total Pelvic Exenteration: Video-Illustrated Technique.” Annals of surgical oncology (2017). PMID: 28808931 ↗
L4CASE_REPORTCited in: Local-Regional Recurrence - [84]
Niazmand A, Nedaeinia R, Vatandoost N et al.. “The impacts of dipeptidyl- peptidase 4 (DPP-4) inhibitors on common female malignancies: A systematic review.” Gene (2024). PMID: 38866262 ↗
L2SR_OBSCited in: Distant Metastatic Disease - [85]
Wang X, Wu Y, Huang J et al.. “Bispecific antibodies (PD-1/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy±bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort study.” Cancer immunology, immunotherapy : CII (2025). PMID: 41136631 ↗
L3COHORTCited in: Distant Metastatic Disease - [86]
Lang J, Liu Q, Ji R et al.. “Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: a case report.” Frontiers in immunology (2025). PMID: 40375998 ↗
L4CASE_REPORTCited in: Distant Metastatic Disease - [87]
Guo L, Liu Y, Zhang S et al.. “Case report: Cutaneous metastasis of squamous cervical carcinoma: complete regression after molecular diagnosis.” Frontiers in immunology (2024). PMID: 39902051 ↗
L4CASE_REPORTCited in: Distant Metastatic Disease - [88]
Ni J, Dong X, Shou H et al.. “Second-line monotherapy with a PD-1/CTLA-4 inhibitor effectively treated multiple brain and lung metastases of cervical cancer: a case report.” Frontiers in immunology (2024). PMID: 39469707 ↗
L4CASE_REPORTCited in: Distant Metastatic Disease - [89]
Zeng Q, Huang S, Jiang T. “The Multiple Roles and Targeting Strategies of LonP1 in the Occurrence and Development of Cancer.” BioFactors (Oxford, England) (2026). PMID: 42219609 ↗
L5REVIEW_NARRATIVECited in: Distant Metastatic Disease - [90]
Xu Z, Zhang L, Wang H et al.. “Combined neutrophil-to-lymphocyte ratio and nomogram for predicting progression-free survival in recurrent/metastatic cervical cancer treated with immune checkpoint inhibitors.” Frontiers in immunology (2026). PMID: 42058197 ↗
L3OTHERCited in: Distant Metastatic Disease - [91]
Liu R, Lin Z, Li Y et al.. “Mechanistic insights into the roles of astragalosides and Astragalus polysaccharides in gynecological and breast cancers (Review).” Oncology reports (2026). PMID: 41860034 ↗
L5REVIEW_NARRATIVECited in: Distant Metastatic Disease - [92]
Liu J, Zhou L, Yao P et al.. “M5C-driven stabilization of SERPINB5 promotes cervical cancer progression and chemotherapy resistance.” Cell death & disease (2026). PMID: 41673397 ↗
L5OTHERCited in: Distant Metastatic Disease - [93]
Yu H, Chen J, Lin J et al.. “Cadonilimab rechallenge in patients with recurrent or metastatic cervical cancer following prior PD-1/PD-L1 inhibitor failure: a retrospective multicenter study.” Frontiers in immunology (2025). PMID: 41583427 ↗
L4OTHERCited in: Distant Metastatic Disease - [94]
Wang M, Fan J, Mu B et al.. “HDAC5 stabilization by tubeimoside I suppresses cervical cancer metastasis via inhibiting H3K27ac/KPNA2 axis.” British journal of cancer (2026). PMID: 41507559 ↗
L5OTHERCited in: Distant Metastatic Disease - [95]
Liu Z, Zhang S, Wang Y et al.. “Development and validation of immunotherapy nomogram for predicting the efficacy and prognosis of recurrent and metastatic cervical cancer.” Frontiers in immunology (2025). PMID: 41438759 ↗
L3OTHERCited in: Distant Metastatic Disease - [96]
Chen L, Chen W, Lin Y et al.. “Serum immune parameters as predictors for treatment outcomes in cervical cancer treated with concurrent chemo-radiotherapy.” Chinese medical journal (2025). PMID: 41199468 ↗
L3OTHERCited in: Distant Metastatic Disease - [97]
Mathibela SP, Ncube KN, Lebelo MT et al.. “Advancing cervical cancer treatment: integrating cannabinoids, combination therapies and nanotechnology.” Journal of cancer research and clinical oncology (2025). PMID: 41102423 ↗
L5REVIEW_NARRATIVECited in: Distant Metastatic Disease - [98]
Lahouti S, Doustvandi MA, Yari A et al.. “Photodynamic therapy boosts the anti-proliferative activity of oxaliplatin in cervical cancer cells by regulating stemness-related genes.” Medical oncology (Northwood, London, England) (2025). PMID: 41081980 ↗
L5OTHERCited in: Distant Metastatic Disease - [99]
Ma Y, Lin S, Chen Q et al.. “Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b study.” Cell reports. Medicine (2025). PMID: 41045933 ↗
L2TRIAL_NONRANDOMCited in: Distant Metastatic Disease - [100]
Jenei V, Muszka Z, Stigelmayer Á et al.. “Anthracycline Treatments and the Presence of Tumor Cells Synergistically Modify the Composition of Macrophage Subpopulations in the Co-Culture System.” International journal of molecular sciences (2025). PMID: 41009763 ↗
L5OTHERCited in: Distant Metastatic Disease - [101]
de Sousa C, Eksteen C, Engelbrecht AM. “Resveratrol: Sensitising CD44+ Cervical Cancer Cells to Carboplatin and Mitigating Metastasis.” Cancer medicine (2025). PMID: 40888184 ↗
L5REVIEW_NARRATIVECited in: Distant Metastatic Disease - [102]
Ito K, Nakajima Y, Ogawa H et al.. “Phase I/II study of stereotactic body radiotherapy boost in patients with cervical cancer ineligible for intracavitary brachytherapy.” Japanese journal of radiology (2024). PMID: 38625476 ↗
L2TRIAL_NONRANDOMCited in: Oligometastatic Disease - [103]
Cengiz M, Dogan A, Ozyigit G et al.. “Comparison of intracavitary brachytherapy and stereotactic body radiotherapy dose distribution for cervical cancer.” Brachytherapy (2012). PMID: 22192496 ↗
L4TRIAL_NONRANDOMCited in: Oligometastatic Disease - [104]
Park HJ, Chang AR, Seo Y et al.. “Stereotactic Body Radiotherapy for Recurrent or Oligometastatic Uterine Cervix Cancer: A Cooperative Study of the Korean Radiation Oncology Group (KROG 14-11).” Anticancer research (2015). PMID: 26254414 ↗
L3TRIAL_NONRANDOMCited in: Oligometastatic Disease - [105]
Ito K, Kito S, Nakajima Y et al.. “Determining the recommended dose of stereotactic body radiotherapy boost in patients with cervical cancer who are unsuitable for intracavitary brachytherapy: a phase I dose-escalation study.” Japanese journal of clinical oncology (2019). PMID: 31112278 ↗
L2TRIAL_NONRANDOMCited in: Oligometastatic Disease - [106]
Peng C, Li X, Tang W et al.. “Real-world outcomes of first-line maintenance therapy for recurrent or metastatic cervical cancer: A multi-center retrospective study.” International immunopharmacology (2024). PMID: 38330795 ↗
L3COHORTCited in: Oligometastatic Disease - [107]
da Silva JL, de Miranda AVSS, Arruda GV et al.. “Stereotactic body radiotherapy as an alternative to brachytherapy in cervical cancer (SCORE): A systematic review and meta-analysis.” Critical reviews in oncology/hematology (2025). PMID: 40460923 ↗
L1SR_OBSCited in: Oligometastatic Disease - [108]
Mendez LC, Leung E, Cheung P et al.. “The Role of Stereotactic Ablative Body Radiotherapy in Gynaecological Cancers: A Systematic Review.” Clinical oncology (Royal College of Radiologists (Great Britain)) (2017). PMID: 28209456 ↗
L2SR_OBSCited in: Oligometastatic Disease - [109]
Chargari C, Renard S, Espenel S et al.. “[Can stereotactic body radiotherapy replace brachytherapy for locally advanced cervical cancer? French society for radiation oncology statement].” Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique (2020). PMID: 32753238 ↗
L5GUIDELINECited in: Oligometastatic Disease - [110]
Shenker R, Stephens SJ, Davidson B et al.. “Role of stereotactic body radiotherapy in gynecologic radiation oncology.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2022). PMID: 35256426 ↗
L5REVIEW_NARRATIVECited in: Oligometastatic Disease - [111]
Miranda AVSS, da Silva JL, Andrade DAP et al.. “Stereotactic body radiotherapy boost as an alternative to brachytherapy for cervical cancer: A scoping review.” Critical reviews in oncology/hematology (2024). PMID: 39299408 ↗
L5REVIEW_NARRATIVECited in: Oligometastatic Disease - [112]
Youn JW, Hur SY, Woo JW et al.. “Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial.” The Lancet. Oncology (2020). PMID: 33271094 ↗
L2TRIAL_NONRANDOMCited in: Prognosis of Recurrent Disease - [113]
Höckel M, Trott S, Dornhöfer N et al.. “Vulvar field resection based on ontogenetic cancer field theory for surgical treatment of vulvar carcinoma: a single-centre, single-group, prospective trial.” The Lancet. Oncology (2018). PMID: 29530664 ↗
L2TRIAL_NONRANDOMCited in: Prognosis of Recurrent Disease - [114]
Höckel M, Horn LC, Manthey N et al.. “Resection of the embryologically defined uterovaginal (Müllerian) compartment and pelvic control in patients with cervical cancer: a prospective analysis.” The Lancet. Oncology (2009). PMID: 19482513 ↗
L2TRIAL_NONRANDOMCited in: Prognosis of Recurrent Disease - [115]
Zhou L, Sun C, Diao P et al.. “Efficacy and safety of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer: a meta-analysis.” Frontiers in immunology (2026). PMID: 41869324 ↗
L1SR_OBSCited in: Prognosis of Recurrent Disease - [116]
Zhou J, Ye W, Ranarisoa SN et al.. “Comparison of drug regimens for recurrent or metastatic cervical cancer: a systematic review and network meta-analysis.” Frontiers in immunology (2026). PMID: 41822503 ↗
L1SR_OBSCited in: Prognosis of Recurrent Disease - [117]
Vincze Á, Márai D, Frivaldszky L et al.. “Neoadjuvant chemotherapy enables fertility preservation without compromising oncologic outcomes in early cervical cancer ≥2 cm: A systematic review and meta-analysis.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41687593 ↗
L1SR_OBSCited in: Prognosis of Recurrent Disease - [118]
Zhuang Q, Liu Y. “Efficacy and safety of Cadonilimab in the treatment of recurrent/metastatic and advanced cervical cancer: a systematic review and meta-analysis.” Frontiers in immunology (2025). PMID: 41601625 ↗
L2SR_OBSCited in: Prognosis of Recurrent Disease - [119]
Saad A, Taylor A, Felder S et al.. “De-escalating first-line treatment in stage IVB or recurrent cervical cancer: outcomes of immunotherapy alone and systemic review.” The oncologist (2025). PMID: 40421960 ↗
L4SR_OBSCited in: Prognosis of Recurrent Disease - [120]
Bale CA, Pearce JV, Deng X et al.. “Prognostic value of FDG-PET SUV changes in cervical cancer following radiation therapy: a retrospective cohort study.” Archives of gynecology and obstetrics (2026). PMID: 41609820 ↗
L3COHORTCited in: Prognosis of Recurrent Disease - [121]
Kim SI, Kim JW, Kwon JS et al.. “Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial.” Gynecologic oncology (2026). PMID: 41520567 ↗
L1RCTCited in: Prognosis of Recurrent Disease - [122]
Kitami K, Kuji S, Kamiya N et al.. “Real-world safety and efficacy of immune checkpoint inhibitors in Japanese patients with persistent, recurrent, or metastatic cervical cancer: a multicenter prospective and retrospective study.” International journal of clinical oncology (2026). PMID: 41504989 ↗
L3COHORTCited in: Prognosis of Recurrent Disease - [123]
Uppal S, Gehrig PA, Peng K et al.. “Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32031867 ↗
L3REVIEW_NARRATIVECited in: Prognosis of Recurrent Disease - [124]
Rose PG, Java J, Whitney CW et al.. “Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25732170 ↗
L2OTHERCited in: Prognosis of Recurrent Disease - [125]
Höckel M, Hentschel B, Horn LC. “Association between developmental steps in the organogenesis of the uterine cervix and locoregional progression of cervical cancer: a prospective clinicopathological analysis.” The Lancet. Oncology (2014). PMID: 24656439 ↗
L2OTHERCited in: Prognosis of Recurrent Disease - [126]
Baudin L, Zanella L, Lebeau A et al.. “Nonmetastatic Para-aortic Lymph Node Remodeling as a Predictor of Outcome in Locally Advanced Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41779008 ↗
L3OTHERCited in: Prognosis of Recurrent Disease